PBAC's latest decision on Isotretinoin: Recommended (2019). Considered for Treatment of severe cystic acne that is unresponsive to other therapy, including systemic antibiotics.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2018
Submissions
2
2018 → 2019
Eligible population
Patients with severe cystic acne unresponsive to conventional therapy, including systemic antibiotics; dose-optimisation population requiring 30 mg daily dose.
Therapy area
Dermatology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Economic model
BIA only
ICER note
Not modelled; this is a minor submission for a new formulation/strength (30 mg capsule) of an already-listed drug. No economic evaluation was performed.